Highbridge Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Highbridge Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-100,000	Closed	-$2.24M	–	1443
2018 Q1	$2.24M	Hold	100,000	–	–	0.04%	423
2017 Q4	$2.5M	Buy	100,000 +49,177	+97%	+$1.2M	0.04%	352
2017 Q3	$1.23M	Buy	50,823 +40,823	+408%	+$960K	0.02%	525
2017 Q2	$202K	Sell	10,000 -18,345	-65%	-$382K	﹤0.01%	1112
2017 Q1	$763K	Sell	28,345 -10,651	-27%	-$217K	0.01%	726
2016 Q4	$741K	Sell	38,996 -40,227	-51%	-$769K	0.01%	635
2016 Q3	$1.55M	Buy	79,223 +43,646	+123%	+$738K	0.02%	474
2016 Q2	$533K	Sell	35,577 -28,968	-45%	-$364K	0.01%	832
2016 Q1	$594K	Buy	+64,545	New	+$783K	0.01%	910

Other funds holding FLXN

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Highbridge Capital Management's FLXN Position: Q2 2018 in Review

Highbridge Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2018, closing a stake of 100,000 shares — an estimated $2.24M sold.

Highbridge Capital Management first reported a position in FLXN in Q1 2016 and held it in 9 quarters. The position peaked at $2.5M in Q4 2017. 130 funds tracked by Wall St. Rank hold FLXN as of Q2 2018.

Highbridge Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 100,000 Flexion Therapeutics, Inc. shares in Q2 2018, an estimated $2.24M.
Highbridge Capital Management first reported a position in Flexion Therapeutics, Inc. in Q1 2016 and held it in 9 quarters.
Highbridge Capital Management's Flexion Therapeutics, Inc. position peaked at $2.5M in Q4 2017.
130 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.